Late effects of disturbed IGF signaling in congenital diseases: Intrauterine and postnatal growth retardation

Endocrine Development

Volumn 11, Issue , 2007, Pages 16-27

  Cianfarani, S ^a   Geremia, C ^a   Puglianiello, A ^a   Maiorana, A ^a   Germani, D ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR; SOMATOMEDIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

BIOLOGICAL MODEL; ENDOCRINE DISEASE; FEMALE; GENETICS; HUMAN; INTRAUTERINE GROWTH RETARDATION; METABOLISM; MUTATION; PHYSIOLOGY; PLACENTA DISORDER; PREGNANCY; REVIEW; SIGNAL TRANSDUCTION; TIME;

ENDOCRINE SYSTEM DISEASES; FEMALE; FETAL GROWTH RETARDATION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MODELS, BIOLOGICAL; MUTATION; PLACENTA DISEASES; PREGNANCY; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; SOMATOMEDINS; TIME FACTORS;

EID: 39549097601     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000111054     Document Type: Conference Paper

References (50)

1. Dupont J, Dunn SE, Berrett JC, Leroith D: Microarray analysis and identification of novel molecules involved in insulin-like growth factor-1 receptor signalling and gene expression. Rec Prog Horm Res 2003;58:325-342.
2. Yarden Y, Ullrich A: Molecular analysis of signal transduction by growth factors. Biochemistry 1988;27:3113-3119.
3. Schumacher R, Mosthaf L, Schlessinger J, Brandenburg D, Ullrich A: Insulin and insulin-like growth factor-1 binding specificity is determined by distinct regions of their cognate receptors. J Biol Chem 1991;266:19288-19295.
4. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E: Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986;5:2503-2512.
5. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-212.
6. White MF: The IRS-1 signalling system. Curr Opin Genet Dev 1994;4:47-54.
7. Cheatham B, Kahn CR: Insulin action and the insulin signalling network. Endocr Rev 1995;16:117-142.
8. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995;16:143-163.
9. Sun XJ, Pons S, Asano T, Myers MG Jr, Glasheen E, White MF: The Fyn tyrosine kinase binds IRS-1 and forms a distinct signalling complex during insulin stimulation. J Biol Chem 1996;271:10583-10587.
10. Lavan BE, Lienhard GE: The insulin-elicited 60-kDa phosphotyrosine protein in rat adipocytes is associated with phosphatidylinositol 3-kinase. J Biol Chem 1993;268:5921-5928.
11. Patti ME, Sun XJ, Bruening JC, Araki E, Lipes MA, White MF, Kahn CR: 4PS/insulin receptor substrate (IRS)-2 is the alternative substrate of the insulin receptor in IRS-1-deficient mice. J Biol Chem 1995;270:24670-24673.
12. Fantin VR, Sparling JD, Slot JW, Keller SR, Lienhard GE, Lavan BE: Characterization of insulin receptor substrate 4 in human embryonic kidney 293 cells. J Biol Chem 1998;273:10726-10732.
13. Winnay JN, Bruning JC, Burks DJ, Kahn CR: Gab-1-mediated IGF-1 signalling in IRS-1-deficient 3T3 fibroblasts. J Biol Chem 2000;275:10545-10550.
14. Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, Nicoletti I, Pawson T, Pelicci PG: A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 1992;70:93-104.
15. Lowenstein EJ, Daly RJ, Batzer AG, Li W, Margolis B, Lammers R, Ullrich A, Skolnik EY, BarSagi D, Schlessinger J: The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signalling. Cell 1992;70:431-442.
16. Skolnik EY, Lee CH, Batzer A, Vicentini LM, Zhou M, Daly R, Myers MJ Jr, Backer JM, Ullrich A, White MF: The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. EMBO J 1993;12:1929-1936.
17. Backer JM, Myers MG Jr, Shoelson SE, Chin DJ, Sun XJ, Miralpeix M, Hu P, Margolis B, Skolnik EY, Schlessinger J: Phosphatidylinositol 3′-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J 1992;11:3469-3479.
18. Xiao S, Rose DW, Sasaoka T, Maegawa H, Burke TR Jr, Roller PP, Shoelson SE, Olefsky JM: Syp (SH-PTP2) is a positive mediator of growth factor-stimulated mitogenic signal transduction. J Biol Chem 1994;269:21244-21248.
19. Sun XJ, Pons S, Asano T, Myers MG Jr, Glasheen E, White MF: The Fyn tyrosine kinase binds IRS-1 and forms a distinct signalling complex during insulin stimulation. J Biol Chem 1996;271:10583-10587.
20. Lee CH, Li W, Nishimura R, Zhou M, Batzer AG, Myers MG Jr, White MF, Schlessinger J, Skolnik EY: Nck associates with the SH2 domain-docking protein IRS-1 in insulin-stimulated cells. Proc Natl Acad Sci USA 1993;90:11713-11717.
21. Beitner-Johnson D, Blakesley VA, Shen-Orr Z, Jimenez M, Stannard B, Wang LM, Pierce J, LeRoith D: The proto-oncogene product c-Crk associates with insulin receptor substrate-1 and 4PS: modulation by insulin growth factor-I (IGF) and enhanced IGF-I signalling, J Biol Chem 1996;271:9287-9290.
22. Blenis J: Signal transduction via the MAP kinases: proceed at your own RSK. Proc Natl Acad Sci USA 1993;90:5889-5892.
23. Crews CM, Erikson RL: Extracellular signals and reversible protein phosphorylation: what to Mek of it all. Cell 1993;74:215-217.
24. Rother KI, Imai Y, Caruso M, Beguinot F, Formisano P, Accili D: Evidence that IRS-2 phosphorylation is required for insulin action in hepatocytes. J Biol Chem 1998;273:17491-17497.
25. Araki E, Lipes MA, Patti ME, Bruning JC, Haag B III, Johnson RS, Kahn CR: Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 1994;372:186-190.
26. Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, Terauchi Y, Ueki K, Kaburagi Y, Satoh S, Sekihara H, Yoshioka S, Horikoshi H, Furuta Y, Ikawa Y, Kasuga M, Yazaki Y, Aizawa S: Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994;372:182-186.
27. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, Bonner-Weir S, White MF: Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998;391:900-904.
28. Baker J, Liu JP, Robertson EJ, Efstratiadis A: Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75:73-82.
29. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A: Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993;75:59-72.
30. Powell-Braxton L, Hollingshead P, Warburton C, Dowd M, Pitts-Meek S, Dalton D, Gillett N, Stewart TA: IGF-I is required for normal embryonic growth in mice. Genes Dev 1993;7:2609-2617.
31. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A: Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 2001;229:141-162.
32. Walenkamp MJE, Karperien M, Pereira AM, Hilhorst-Hofstee Y, van Doorn J, Chen JW, Mohan S, Denley A, Forbes B, van Duyvenvoorde HA, van Thiel SW, Sluimers CA, Bax JJ, de Laat JAPM, Breuning MB, Romijn JA, Wit JM: Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol Metab 2005;90:2855-2864.
33. Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, Keller E, Kiess W, Klammt J, Kratzsch J, Osgood D, Pfäffle R, Raile K, Seidel B, Smith RJ, Chernausek SD: IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 2003;349:2211-2222.
34. Kawashima Y, Kanzaki S, Yang F, Kinoshita T, Hanaki K, Nagaishi Ji, Ohtsuka Y, Hisatome I, Ninomoya H, Nanba E, Fukushima T, Takahashi SI: Mutation at cleavage site of insulin-like growth factor receptor in a short-stature child born with intrauterine growth retardation. J Clin Endocrinol Metab 2005;90:4679-4687.
35. Walenkamp MJE, van der Kamp HJ, Pereira AM, Kant SG, van Duyvenvoorde HA, Kruithof MF, Breuning MH, Romijn JA, Karperien M, Wit JM: A variable degree of intrauterine and postnatal growth retardation in a family with a missense mutation in the insulin-like growth factor I receptor. J Clin Endocrinol Metab 2006;91:3062-3070.
36. Kiess W, Kratzsch J, Keller E, Schneider A, Raile K, Klammt J, Seidel B, Garten A, Schmidt H, Pfäffle R: Clinical examples of disturbed IGF signalling: intrauterine and postnatal growth retardation due to mutations of the insulin-like growth factor I receptor (IGF-IR) gene. Rev Endocr Metab Disord 2005;6:183-187.
37. Roback EW, Barakt AJ, Dev VG, Mbikay M, Chretien M, Butler MG: An infant with deletion of the distal long arm of chromosome 15 (q26.1-qter) and loss of IGF-I receptor gene. Am J Med Genet 1991;38:74-79.
38. Nagai T, Shimokawa O, Harada N, Sakazume S, Ohashi H, Matsumoto N, Obata K, Yoshino A, Murakami N, Murai T, Sakuta R, Niikawa N: Postnatal overgrowth by 15q-trisomy and intrauterine growth retardation by 15q-monosomy due to familial translocation t(13;15): dosage effect of IGF-IR? Am J Med Genet 2002;113:173-177.
39. Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, Terauchi Y, Ueki K, Kaburagi Y, Satoh S, Sekihara H, Yoshioka S, Horikoshi H, Furuta Y, Ikawa Y, Kasuga M, Yazaki Y, Aizawa S: Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994;372:182-186.
40. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, Bonner-Weir S, White MF: Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998;391:900-903.
41. Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, White MF: IRS-2 coordinates Igf-1 receptor-mediated β-cell development and peripheral insulin signalling. Nature 1999;23:32-40.
42. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ: Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 2001;42:38349-38352.
43. Fowden AL: The insulin-like growth factors and feto-placental growth. Placenta 2003;24:803-812.
44. Laviola L, Perrini S, Belsanti G, Natalicchio A, Montrone C, Leonardini A, Vimercati A, Scioscia M, Selvaggi L, Giorgino R, Greco P, Giorgino F: Intrauterine growth restriction in humans is associated with abnormalities in placental insulin-like growth factor signalling. Endocrinology 2005;146:1498-1505.
45. Mudgett JS, Ding J, Guh-Siesel L, Chartrain NA, Yang L, Gopal S, Shen MM: Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis. Proc Natl Acad Sci USA 2000;97:10454-10459.
46. Adams RH, Porras A, Alonso G, Jones M, Vintersten K, Panelli S, Valladare A, Perez L, Klein R, Nebreda AR: Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol Cell 2000;6:109-116.
47. Desai J, Holt-Shore V, Torry RJ, Caudle MR, Torry DS: Signal transduction and biological function of placenta growth factor in primary human trophoblast. Biol Reprod 1999;60:887-892.
48. Hannke-Lohmann A, Pildner von Steinburg S, Dehne K, Benard V, Kolben M, Schmitt M, Lengyel E: Downregulation of a mitogen-activated protein kinase signalling pathway in the placentas of women with preeclampsia. Obstet Gynecol 2000;96:582-587.
49. Khong TY, De Wolf F, Robertson WB, Brosens I: Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986;93:1049-1059.
50. Kliman HJ, Nestler JE, Sermasi E, Sanger JM, Strauss JF: Purification, characterization, and in vitro differentiation of cytotrophoblasts from human term plancentae. Endocrinology 1986;118:1567-1582.